| Tara Leigh Hunter, LPN | |
|
2210 N. Eldorado Ave, Klamath Falls, OR 97601 | |
| (541) 883-1030 | |
| (541) 884-2338 |
| Full Name | Tara Leigh Hunter |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 2210 N. Eldorado Ave, Klamath Falls, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053841643 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 201407759 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tara Leigh Hunter, LPN 2210 N Eldorado Ave, Klamath Falls, OR 97601-6418 Ph: (541) 883-1030 | Tara Leigh Hunter, LPN 2210 N. Eldorado Ave, Klamath Falls, OR 97601 Ph: (541) 883-1030 |
News Archive
Flexion Therapeutics, Inc., today reported that its lead compound FX006, a novel intra-articular, sustained release steroid, demonstrated pain relief that is of both greater magnitude and longer duration than the most commonly prescribed immediate release steroid, triamcinolone acetonide, in a Phase 2b dose-ranging trial in osteoarthritis.
N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.
Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
In searching for a simple way to identify individuals with smoking-related lung injury, scientists at Weill Cornell Medical College have stumbled upon a potential explanation for why the class of pain-relievers known as COX-2 inhibitors increases the risk of heart problems among users.
› Verified 2 days ago
Robin Lea Jordan, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 725 Washburn Way, Klamath Falls, OR 97603 Phone: 541-882-7291 | |
Laura Cobian, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2074 S 6th St, Klamath Falls, OR 97601 Phone: 541-885-2011 | |
Erin Christine Streed, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2210 N Eldorado Ave, Klamath Falls, OR 97601 Phone: 541-883-1030 Fax: 541-884-2338 | |
Vanessa Spillane, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2555 Main St, Klamath Falls, OR 97601 Phone: 541-883-2795 | |
Jennifer Lynn Stapleton, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2210 N Eldorado Ave, Klamath Falls, OR 97601 Phone: 541-883-1030 Fax: 541-884-2338 | |
Mrs. Susan Leigh Thomas, LPN,QMHA Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2210 N Eldorado Ave, Klamath Falls, OR 97601 Phone: 541-883-1030 Fax: 541-884-2338 |